Avelumab in chemotherapy-refractory metastatic Merkel cell carcinoma: Subgroup analysis of efficacy.

被引：0
|
作者：
Kaufman, Howard L.
Russell, Jeffrey
Hamid, Omid
Bhatia, Shailender
Terheyden, Patrick
D'Angelo, Sandra P.
Shih, Kent C.
Lebbe, Celeste
Linette, Gerald P.
Milella, Michele
Brownell, Isaac
Lewis, Karl D.
Lorch, Jochen H.
von Heydebreck, Anja
Mahnke, Lisa
Nghiem, Paul
机构：
[1] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
[2] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[3] Angeles Clin & Res Inst, Los Angeles, CA USA
[4] Univ Washington, Med Ctr, South Lake Union, Seattle, WA 98195 USA
[5] Univ Lubeck, Lubeck, Germany
[6] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[7] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA
[8] CHU Paris, GH St Louis Lariboisiere F Widal, Hosp St Louis, Paris, France
[9] Univ Washington, Sch Med, Seattle, WA 98195 USA
[10] Ist Nazl Tumori Regina Elena IRCCS, Rome, Italy
[11] Natl Canc Inst, Bethesda, MD USA
[12] Univ Colorado Denver, Sch Med, Aurora, CO USA
[13] Dana Farber Canc Inst, Boston, MA 02115 USA
[14] Merck KGaA, Darmstadt, Germany
[15] EMD Serono, Billerica, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 07期
关键词：
D O I：
10.1200/JCO.2017.35.7_suppl.80
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
80
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Integrative molecular analysis of metastatic Merkel cell carcinoma to identify predictive biomarkers of response to avelumab.
    Georges, Sara
    Shah, Parantu K.
    Shapiro, Irina
    Hicking, Christine
    Lu, Lei
    Hennessy, Meliessa
    D'Angelo, Sandra P.
    Cai, Ti
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [42] Apatinib plus radiotherapy or not in chemotherapy-refractory recurrent or metastatic oral squamous cell carcinoma: A pilot study
    Wu, Hui
    Lu, Xiaoxu
    Xu, Jing
    Sun, Xueming
    Wang, Shujuan
    Du, Wei
    Liu, ShanTing
    Li, DingJie
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [43] RETIFANLIMAB VS AVELUMAB IN PATIENTS WITH METASTATIC MERKEL CELL CARCINOMA: A COST-UTILITY ANALYSIS IN ITALY
    Ghetti, G.
    Porta, C.
    Povero, M.
    Trimarchi, C.
    VALUE IN HEALTH, 2024, 27 (12) : S66 - S66
  • [44] Successful rechallenge with avelumab in Merkel cell carcinoma
    Amiot, Mathilde
    Possenti, Florence Brunet
    Lebbe, Celeste
    Baroudjian, Barouyr
    EUROPEAN JOURNAL OF CANCER, 2021, 153 : 96 - 97
  • [45] Avelumab Approved indication: Merkel cell carcinoma
    不详
    AUSTRALIAN PRESCRIBER, 2018, 41 (02) : 55 - 55
  • [46] Immunotherapy in Merkel cell carcinoma: role of Avelumab
    Palla, Amruth R.
    Doll, Donald
    IMMUNOTARGETS AND THERAPY, 2018, 7 : 15 - 19
  • [47] Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program
    Walker, John W.
    Lebbe, Celeste
    Grignani, Giovanni
    Nathan, Paul
    Dirix, Luc
    Fenig, Eyal
    Ascierto, Paolo Antonio
    Sandhu, Shahneen
    Munhoz, Rodrigo
    Benincasa, Elena
    Flaskett, Sarah
    Reed, Josh
    Engelsberg, Arne
    Hariharan, Subramanian
    Kasturi, Vijay
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
  • [48] COST-EFFECTIVENESS OF AVELUMAB IN THE TREATMENT OF PATIENTS WITH METASTATIC MERKEL CELL CARCINOMA IN PORTUGAL
    Pinheiro, B.
    Silva Miguel, L.
    Alarcao, J.
    Palencia, R.
    Borges, M.
    VALUE IN HEALTH, 2020, 23 : S432 - S432
  • [49] Apatinib Plus Radiation Therapy or Not in Chemotherapy-Refractory Recurrent or Metastatic Oral Squamous Cell Carcinoma: A Pilot Study
    Wu, H.
    Lu, X.
    Xu, J.
    Sun, X.
    Wang, S.
    Du, W.
    Liu, S.
    Li, D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E358 - E358
  • [50] Durable remission after rechallenge with ipilimumab and nivolumab in metastatic Merkel cell carcinoma refractory to avelumab: Any role for sequential immunotherapy?
    Khaddour, Karam
    Rosman, Ilana S.
    Dehdashti, Farrokh
    Ansstas, George
    JOURNAL OF DERMATOLOGY, 2021, 48 (02): : E80 - E81
12345